Tocilizumab 8 mg/kg + MTX/DMARD probably leads to lower total withdrawals compared with placebo + MTX/DMARD (moderate certainty).
Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in withdrawals due to Adverse events compared with placebo + MTX/DMARD (high certainty).
Golimumab 50 mg every 4 weeks + MTX leads to higher ACR50 compared with placebo + MTX (high certainty).
Golimumab 50 mg every 4 weeks + MTX leads to higher disease activity (DAS Remission) compared with placebo + MTX (high certainty).
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in adverse Events compared with placebo + MTX (high certainty).
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in serious Adverse Events compared with placebo + MTX (high certainty).
Golimumab 50 mg every 4 weeks + MTX leads to lower all Withdrawals compared with placebo + MTX (high certainty).
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in withdrawals due to Adverse Events compared with placebo + MTX (high certainty).
MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).
MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).
MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of DMARDs naive… compared with MTX monotherapy (moderate certainty).
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of MTX inadequate… compared with MTX monotherapy (moderate certainty).
It is very uncertain whether MTX combination changes withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs… compared with MTX monotherapy (very low certainty).
It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).
It is very uncertain whether the intervention changes pain Various pain scales Median (very low certainty).
It is very uncertain whether the intervention changes function Various validated function scales Median (very low certainty).
The intervention showed no clear difference in number of patients experiencing any adverse event Median (low certainty).